evipedia.ai
← Back

Telmisartan for Health & Longevity

Created on 10/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Telmisartan is a long-acting prescription medication for high blood pressure. Its best-supported effects are lower blood pressure and less protein leakage into urine; in high-risk people it prevented heart attack and stroke about as well as a standard alternative. Memory, liver and lifespan benefits were not shown. Main risks: dizziness, high potassium, reduced kidney filtering, harm to an unborn child. With normal blood pressure, its longevity case remains uncertain. (Full Review)

Protocol

Standard hypertension dose
40 mg once daily
Range 40–80 mg; doses above 80 mg add little; some patients do well on 20 mg
Cardiovascular risk-reduction dose
80 mg once daily
The regimen tested in ONTARGET and TRANSCEND; whether lower doses reduce events is not known
Time of day
Morning or evening
Equal cardiovascular outcomes with usual blood pressure medications; with or without food
Time to effect
Blood pressure
Most effect within 2 weeks
Falls after the first dose; maximum by about 4 weeks
Albumin and metabolic changes
Assessed over months
Albumin benefit mainly in people who already leak albumin

Benefits

Contraindications
  • Pregnant women, at any stage, and women planning pregnancy
  • Breastfeeding women
  • People with prior anaphylaxis or angioedema from telmisartan
  • People taking aliskiren who have diabetes or eGFR below 60 mL/min
  • People with severe liver disease or bile-flow obstruction
  • People with chronic kidney disease and pretreatment potassium above 5.0 mmol/L
    •
Key Interactions
  • ACE inhibitors (ramipril, lisinopril): Raised hypotension, fainting, kidney dysfunction and hyperkalemia without extra benefit; avoid
  • Potassium-raising products (potassium chloride supplements, potassium-containing salt substitutes, spironolactone): Hyperkalemia
  • NSAIDs (such as ibuprofen and naproxen) and COX-2 inhibitors (such as celecoxib): Possible acute kidney failure in older, dehydrated or kidney-impaired people, and blunted blood pressure lowering
  • Lithium: Reversible rises in lithium levels and toxicity
  • Digoxin: Raised digoxin levels, risking toxicity
  • Rosuvastatin: Raised rosuvastatin levels, possibly increasing statin muscle side effects
  • Metformin: Lowered metformin exposure, with a modest effect on glucose response
  • Mycophenolate mofetil: Lowered mycophenolic acid exposure, risking weaker immunosuppression
  • Nisoldipine: Raised telmisartan exposure, which could add to blood pressure lowering
  • PDE5 inhibitors (such as tadalafil and sildenafil): Further blood pressure lowering, adding dizziness risk
  • CYP2C19 substrates (omeprazole, citalopram, clopidogrel): In-vitro inhibition could raise omeprazole or citalopram levels or reduce clopidogrel activation; no human study has tested it
    •
Theoretical (inferred from mechanism)
  • Blood pressure-lowering supplements (beetroot nitrate, garlic extract, magnesium): Additive dizziness or hypotension
  • Alpha-blockers (such as tamsulosin and doxazosin): Orthostatic hypotension
  • UGT enzyme inducers (rifampin, carbamazepine): Weaker blood pressure control
  • Licorice (glycyrrhizin-containing products): Raised blood pressure and potassium loss
  • Alcohol: Lightheadedness or fainting
    •

Risk & Side Effects

  • High: Low blood pressure, dizziness and fainting
    •
  • Medium: Decline in kidney function; hyperkalemia; back pain, upper airway infections and diarrhea; leg pain on walking and skin ulcers; fall in hemoglobin
    •
  • Low: Fetal injury; angioedema and other allergic reactions; new cancer diagnoses; sepsis; liver injury; muscle pain and rhabdomyolysis; low blood sodium; low blood sugar in people with diabetes; raised uric acid; low platelet count and raised eosinophils; erectile dysfunction
    •
  • Speculative:

Monitoring

Marker Target Why
Home blood pressure Systolic below 120 mm Hg Core efficacy marker
Serum potassium 3.5–5.0 mmol/L Safety check; high values change or stop use
Creatinine and eGFR Creatinine about 0.6–1.3 mg/dL; eGFR: no established target, track change from own baseline Safety check; large falls change use
Urine albumin-to-creatinine ratio No established target; track change from own baseline Expected to change in those with albuminuria
HbA1c 4.0–5.6% Expected to change modestly in insulin resistance
Fasting glucose Not specified in the ER Paired with HbA1c
ALT Below the laboratory's upper limit of normal Safety check; rises prompt review
Digoxin or lithium levels Not specified in the ER Safety check for toxicity; only with those drugs
Pregnancy test Not specified in the ER Eligibility check at baseline, where relevant
Creatine kinase Not specified in the ER Usual test for muscle pain or weakness

Cadence: Baseline testing before starting; potassium and eGFR at 1–2 weeks after starting and after each dose increase; home blood pressure several times weekly for the first month, then weekly; potassium, eGFR, urine albumin and HbA1c every 6–12 months once stable.

Qualitative Assessment

  • Lightheadedness or dizziness on standing, especially in the morning or after exercise
  • Energy levels and fatigue during the first weeks
  • Exercise tolerance and recovery
  • Muscle pain or weakness
  • Any swelling of the lips, tongue or face, a medical emergency
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.